Cargando…

Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceccacci, Elena, Minucci, Saverio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800301/ https://www.ncbi.nlm.nih.gov/pubmed/26908329 http://dx.doi.org/10.1038/bjc.2016.36

Ejemplares similares

Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
por: Sim, Wynne, et al.
Publicado: (2022)

Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
por: Schizas, Dimitrios, et al.
Publicado: (2018)

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
por: Groselj, B, et al.
Publicado: (2013)

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
por: Nolan, L, et al.
Publicado: (2008)

Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: A TRAnsition to targeted therapies
por: Arteaga, M F, et al.
Publicado: (2015)

Akt as a target for cancer therapy: more is not always better (lessons from studies in mice)
por: Wang, Qi, et al.
Publicado: (2017)

Childhood leukaemia, nuclear sites, and population mixing
por: Kinlen, L
Publicado: (2011)

The clinical implications of gene mutations in chronic lymphocytic leukaemia
por: Rossi, Davide, et al.
Publicado: (2016)

MicroRNAs: new players in acute myeloid leukaemia
por: Havelange, V, et al.
Publicado: (2009)

Genome-wide functions of PML–RARα in acute promyelocytic leukaemia
por: Saeed, S, et al.
Publicado: (2011)

Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
por: Kerantzas, Christopher A., et al.
Publicado: (2017)

Cancer chemoprevention: lessons learned and future directions
por: Brenner, D E, et al.
Publicado: (2005)

The Effect of Organoselenium Compounds on Histone Deacetylase Inhibition and Their Potential for Cancer Therapy
por: Adimulam, Theolan, et al.
Publicado: (2021)

Hepatic encephalopathy: Lessons from preclinical studies
por: Lima, Luiza Cioglia Dias, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Mutation Hotspots in the β-Catenin Gene: Lessons from the Human Cancer Genome Databases
por: Kim, Sewoon, et al.
Publicado: (2019)

The Origin of Mucosal Immunity: Lessons from the Holobiont Hydra
por: Schröder, Katja, et al.
Publicado: (2016)

Parental squabbles and genome expression: lessons from the polyploids
por: Pignatta, Daniela, et al.
Publicado: (2009)

Systemic Amyloidosis: Lessons from β(2)-Microglobulin
por: Stoppini, Monica, et al.
Publicado: (2015)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibition in Candida Species
por: Garnaud, Cécile, et al.
Publicado: (2016)

How Chromosome Mis-Segregation Leads to Cancer: Lessons from BubR1 Mouse Models
por: Lee, Hyunsook
Publicado: (2014)

Lessons learned from study of congenital hip disease in adults
por: Hartofilakidis, George, et al.
Publicado: (2016)

Reconstructing prokaryotic transcriptional regulatory networks: lessons from actinobacteria
por: Venancio, Thiago M, et al.
Publicado: (2009)

Individualized diabetes care: Lessons from the real-world experience
por: Khor, Xiao Ying, et al.
Publicado: (2023)

Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
por: Manzotti, Gloria, et al.
Publicado: (2019)

Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects
por: Polani, Faran, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Microvasculature of the esophagus and gastroesophageal junction: Lesson learned from submucosal endoscopy
por: Maselli, Roberta, et al.
Publicado: (2016)

COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions
por: Triggle, Chris R., et al.
Publicado: (2020)

ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
por: Perrotti, D, et al.
Publicado: (2006)

ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia
por: Canaani, E, et al.
Publicado: (2004)

Modifications of histone cores and tails in V(D)J recombination
por: Muegge, Kathrin
Publicado: (2003)

Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

Potential use of histone deacetylase inhibitors in cancer therapy
por: Gołąbek, Karolina, et al.
Publicado: (2015)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
por: Tu, Bin, et al.
Publicado: (2020)

Histone deacetylases modulate resistance to the therapy in lung cancer
por: Contreras-Sanzón, Estefanía, et al.
Publicado: (2022)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
por: Guo, Fengyi, et al.
Publicado: (2022)

Targeting histone deacetylases for cancer therapy: Trends and challenges
por: Liang, Tao, et al.
Publicado: (2023)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i1sc0r267l05dmngqhk49tg7ge